Grouport, a mental healthcare startup based in New York, has raised $1.5 million in seed funding to assist in the treatment of chronic psychological disorders.
XV Venture Capital led the seed funding round, which also counted with participation from Taub Ventures and 380 Cap, a firm founded by Drizly’s co-founder Justin Robinson. This investment will be used to expand the startup’s evidence-based and tech-enabled platform, allowing the creation of a better support setting for patients with shared experiences.
Co-founded in 2019 by Jonathan Spievack and Mordechai Teitz, Grouport aims to pioneer the virtual group-based treatment industry when it comes to chronic psychological disorders. Its online therapy groups allow patients to meet with the same members and therapists on a weekly basis, providing consistent care to improve the results of the therapeutic efforts.
Since its founding, the startup has facilitated thousands of session attendances and has grown over 10 times. Participants report that the platform has helped them by reducing their symptoms while also allowing them to build better relationships, increase their productivity at work, and improve their overall quality of life. Jonathan Spievack, Founder and CEO of Grouport, referred to this success by stating:
“At Grouport, we’re building a collaborative approach to mental health care that gives people the ability to confide in others facing similar challenges and helps them get better together. Many people feel completely alone and can’t fathom that there are others like them out there feeling the same way they do. We’re here to normalize their experience, destigmatize a lot of what’s keeping them stuck, and help them stay motivated to regularly implement difficult behavioral change into their lives,”
The mental healthcare startup is also looking to expand its leadership teams in the marketing, tech, product, and business development departments, allowing it to expand its presence in the United States to better accommodate the increasing demand resulting from the Covid19 pandemic.
